Cubist Cidecin NDA For Mid-2002; Launch Will Need Up To 150 Reps, CEO Says

Cubist's will file an NDA for its intravenous antibiotic Cidecin (daptomycin) in mid-2002, CEO Scott Rocklage told analysts during Bear Stearns' "virtual" healthcare conference Sept. 24.